These results provide novel evidence of the role of miR-206 in BCRP inhibition and anticancer drug resistance, and clearly demonstrate the miR-206 contribution to BCRP reduction in NRF2-silenced cancer cells. This evidence concerns the gene ABCG2 and cancer.